| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
|
JAMA
|
2010
|
8.93
|
|
2
|
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population.
|
Nat Genet
|
2010
|
4.96
|
|
3
|
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.
|
Lancet
|
2011
|
4.73
|
|
4
|
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.
|
J Clin Oncol
|
2009
|
4.56
|
|
5
|
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.
|
J Clin Oncol
|
2006
|
4.19
|
|
6
|
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
|
J Clin Oncol
|
2008
|
3.54
|
|
7
|
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.
|
Am J Hum Genet
|
2008
|
3.41
|
|
8
|
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.
|
Clin Cancer Res
|
2009
|
2.90
|
|
9
|
Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
|
J Clin Oncol
|
2009
|
2.05
|
|
10
|
Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.
|
J Clin Oncol
|
2010
|
2.03
|
|
11
|
Evolutionary pathways in BRCA1-associated breast tumors.
|
Cancer Discov
|
2012
|
2.01
|
|
12
|
Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
|
Cancer Epidemiol Biomarkers Prev
|
2012
|
1.78
|
|
13
|
Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities.
|
Mol Cancer Ther
|
2012
|
1.72
|
|
14
|
Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer.
|
J Clin Oncol
|
2010
|
1.56
|
|
15
|
Molecular profiling of human mammary gland links breast cancer risk to a p27(+) cell population with progenitor characteristics.
|
Cell Stem Cell
|
2013
|
1.14
|
|
16
|
Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy.
|
J Clin Oncol
|
2007
|
1.08
|
|
17
|
Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes.
|
Cancer Res
|
2011
|
1.05
|
|
18
|
Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers.
|
Breast Cancer Res
|
2009
|
1.04
|
|
19
|
Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.
|
Clin Breast Cancer
|
2007
|
1.01
|
|
20
|
Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers.
|
Cancer Res
|
2009
|
1.01
|
|
21
|
Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer.
|
Clin Breast Cancer
|
2011
|
0.96
|
|
22
|
Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers.
|
Breast Cancer Res Treat
|
2010
|
0.93
|
|
23
|
Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers.
|
Breast Cancer Res Treat
|
2014
|
0.93
|
|
24
|
Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers.
|
J Clin Oncol
|
2012
|
0.91
|
|
25
|
Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling.
|
BMC Res Notes
|
2013
|
0.91
|
|
26
|
A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers.
|
Cancer Epidemiol Biomarkers Prev
|
2012
|
0.89
|
|
27
|
The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer.
|
Clin Breast Cancer
|
2008
|
0.88
|
|
28
|
Genetic variation in IGF2 and HTRA1 and breast cancer risk among BRCA1 and BRCA2 carriers.
|
Cancer Epidemiol Biomarkers Prev
|
2011
|
0.84
|
|
29
|
Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers.
|
Cancer Epidemiol Biomarkers Prev
|
2011
|
0.83
|
|
30
|
Capecitabine/Taxane combination therapy: evolving clinical utility in breast cancer.
|
Clin Breast Cancer
|
2006
|
0.82
|
|
31
|
Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers.
|
Breast Cancer Res Treat
|
2014
|
0.81
|
|
32
|
Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer.
|
Clin Breast Cancer
|
2005
|
0.80
|
|
33
|
Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma.
|
Cancer
|
2003
|
0.75
|
|
34
|
Family environments of women seeking BRCA1/BRCA2 genetic mutation testing: an exploratory analysis.
|
J Genet Couns
|
2004
|
0.75
|